Adenosine triphosphate
DrugInfusion of 2.5g of ATP in 500 mL of saline solution. (IV)
Other names: ATP
NCT Number: NCT02279511
To Check whether systemic treatment with ATP alters the profile of cerebral metabolism in patients with Alzheimer's disease using MRS techniques (Magnetic Resonance Spectroscopy) and adjust the infusion (minimum effective dose) that promotes this metabolic change.
Looking for future studies?
Notify Me55 year–85 year
All sexes
Interventional
Phase 2
Fundació ACE, Barcelona, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
Other names: ATP
Infusion of 500 mL of saline solution. (IV)
Time frame: expected average of 7-25 hours post infusion
Spectroscopy will be taken one hour after the infusion (7h for patients allocated to 6h arm and 25h in 24h infusion arm)
Time frame: expected average of 7-25 hours post infusion
one hour after the infusion (7h for patients allocated to 6h arm and 25h in 24h infusion arm)
Time frame: 3 months compared to baseline.
The cogstate is a software used to evaluate cognitive impairment
Time frame: 3 months compared to baseline.
Time frame: post treatment or 3 months post baseline
Time frame: an expected average of 90 days
Time frame: at 90 days
Sara Varea
Other
Evaluating the Effectiveness of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in Patients With Moderate Alzheimer's Disease and Severe: Double-blind Dose Finding Clinical Trial.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05519137
Alzheimer Disease, Alzheimer's Disease
Menands, New York, United States
View Trial DetailsNCT04867616
Alzheimer Disease, Alzheimer's Disease
Fresno, California, United States
View Trial DetailsNCT02947893
Alzheimer Disease, Alzheimer's Disease
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06206824
Abnormalities, Multiple, Alzheimer Disease
Gières, France
View Trial Details